4CYTE draws attention as proactive joint health option

A new dvm360 podcast feature is giving fresh visibility to 4CYTE, a plant-based joint supplement for dogs and horses that’s been building its US presence through epiq Animal Health. In the episode, Mindy Cannon, MBA, described 4CYTE as a supplement centered on Epiitalis, a patented plant-derived ingredient positioned to support joint cartilage growth and joint function, with use cases ranging from preventive support to maintenance and adjunctive care. (dvm360.com)

The timing matters because osteoarthritis and mobility support continue to be major discussion points in companion animal and equine medicine, and supplements remain a category where client demand often moves faster than consensus evidence. According to dvm360, 4CYTE entered US animal health distribution nearly two years before the podcast through a partnership between epiq Animal Health and Interpath Global. A company announcement in April 2025 said the horse product launched first in December 2024, followed by the dog product in April 2025, as the partners expanded access through US animal health distribution channels. (dvm360.com)

The core product claims are familiar to veterinarians working in mobility care. Cannon said 4CYTE can be used alone or alongside other treatment options, is intended for long-term use, and is suitable from six months of age. The dvm360 piece also highlighted practical selling points for clinics and pet parents, including palatability, dosing, cost discussion, and channel availability through distributors and e-commerce. Those details suggest the story here isn’t just a product explainer, but part of a broader commercialization effort aimed at embedding the supplement in everyday preventive and maintenance joint-health conversations. (dvm360.com)

On the evidence side, there is published research behind the ingredient, but the picture is still nuanced. A 2020 PubMed-indexed pilot study in dogs with naturally occurring osteoarthritis reported improvement after one month of treatment, but it was an open-label pilot rather than a blinded, placebo-controlled pivotal trial. In horses, a 2022 Frontiers in Veterinary Science study evaluated Biota orientalis, the plant source associated with Epiitalis, in an experimental osteoarthritis model; the paper framed the work around biomarker and disease-modification questions, but it was a small study in a surgically induced model, not a real-world field trial. (pubmed.ncbi.nlm.nih.gov)

That limited-but-growing evidence base fits with broader industry guidance. AAHA’s 2022 pain management guidelines state that the overall strength of evidence for nutraceuticals to relieve clinical signs of osteoarthritis in dogs is low, with omega-3 fatty acids the main exception called out in the guideline summary. AAHA also emphasizes that chronic pain management should be multimodal, combining tools such as weight management, rehabilitation, exercise, environmental modification, pharmaceuticals, and selected adjunctive therapies. In other words, products like 4CYTE may appeal to pet parents and clinicians looking for earlier or additional support, but they’re entering a practice environment that increasingly expects evidence-guided positioning rather than broad supplement claims. (aaha.org)

There’s also a regulatory and communication angle for practices. The National Animal Supplement Council notes that animal health supplements are generally regulated differently from approved drugs, with marketing and labeling boundaries that matter for how products are discussed in clinic. For veterinarians, that means product recommendations should stay grounded in intended use, available evidence, and patient-specific planning, especially when pet parents interpret “preventive” language as a promise of disease avoidance rather than supportive care. (nasc.cc)

Why it matters: For veterinary professionals, this story is less about a single podcast and more about the continued normalization of joint supplements in preventive care conversations. Clinics are likely to see more questions from pet parents about starting mobility support earlier, combining supplements with prescription therapies, or using products before radiographic or clinical osteoarthritis is fully established. That creates an opportunity for veterinarians to lead with a structured framework: assess body condition, mobility, pain, and lifestyle risk; explain where evidence is stronger or weaker; and position supplements, if used, within a broader plan rather than as a replacement for proven care pathways. (aaha.org)

What to watch: The next meaningful signals will be whether 4CYTE generates stronger controlled clinical data in dogs or horses, how quickly US distribution expands through veterinary channels, and whether more clinicians publicly weigh in on where Epiitalis-based products belong in multimodal osteoarthritis management. (prnewswire.com)